Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Net Income

Bottom-line profit after all expenses, interest, and taxes.

Viatris Inc.NASDAQ: VTRS

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income remains negative

Q2 FY2026 net income was -$118.8M, compared with -$4.6M a year earlier. Trailing-twelve-month net income was -$410.7M.

Context

  • Net income amounted to 24.6% of revenue in FY2025, up 20.3 pp from a year earlier.
  • Net income increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 7 analysts of $3.03B (+186.1%) for the fiscal year ending Dec 2026, a step up from the -454.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$118.8M-167.3% QoQ
Last fiscal yearDec 2025
-$3.51B-454.2% YoY
LTMJun 2026
-$410.7M+88.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2482.6%+670.4%+3153.0 pp
1 year-454.2%+186.1%+640.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(3.51B) USD
Year-over-year change
-454.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How VTRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +88.2% is the 4th highest of 9, against a peer median of -48.1%.
  • Net income amounts to 2.8% of revenue for VTRS, versus a peer median of 8.5%.
VTRS Competitors
Net Income for VTRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹28.03B INR-52.2%+0.0%8.5%
HLNHaleon plcLTM Jun 2025£2.41B GBP—+15.4%14.6%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$706M USD+546.8%—4.1%
OGNOrganon & Co.LTM Sep 2026$213M USD-57.5%-41.1%3.5%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$157.36M USD+4562.6%—5.0%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$89.67M USD+526.0%—9.7%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$79.23M USD-44.1%+2.4%11.0%
ALKSAlkermes plcLTM Sep 2026-$351K USD-100.1%—0.0%
VTRSViatris Inc.LTM Jun 2026-$410.7M USD+88.2%—2.8%
BHCBausch Health Companies Inc.LTM Jun 2026-$1.1B USD-1220.4%—10.1%
Peer median (excluding VTRS) —-48.1%+1.2%8.5%

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.89B16.26B15.43B14.74B14.3B
Cost of Revenue12.31B9.77B8.99B9.12B9.29B
Gross Profit5.58B6.5B6.44B5.62B5.01B
Gross Margin31.2%40.0%41.7%38.2%35.1%
Research & Development681M662.2M805.2M808.7M965.9M
Selling, General & Admin4.53B4.18B4.65B4.43B3.79B
Operating Expenses5.61B4.88B5.67B5.61B7.68B
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
EBITDA4.48B6.43B3.52B2.64B(395.4M)
EBITDA Margin25.0%39.6%22.8%17.9%-2.8%
Operating Income(34M)1.61B766.2M10.1M(2.66B)
Operating Margin-0.2%9.9%5.0%0.1%-18.6%
Interest Income00000
Interest Expense636.2M592.4M573.1M550M471.3M
Other Income / Expenses(630.4M)1.2B(563.3M)(633.3M)(1B)
Income Before Tax(664.4M)2.81B202.9M(623.2M)(3.67B)
Pre-Tax Margin-3.7%17.3%1.3%-4.2%-25.6%
Income Tax Expense604.7M734.6M148.2M11M(150.1M)
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Net Margin-7.1%12.8%0.4%-4.3%-24.6%
EPS (Basic)(1.05)1.710.05(0.53)(3.00)
EPS (Diluted)(1.05)1.710.05(0.53)(3.00)
Weighted Avg Shares1.21B1.21B1.2B1.19B1.17B
Weighted Avg Shares (Diluted)1.21B1.22B1.21B1.19B1.17B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.